References
- Joint Food and Agriculture Organization/World Health Organization. FAO-WHO Expert Committee on Brucellosis (sixth report). WHO Technical Report Series No. 740. Geneva: World Health Organisation; 1986. p. 56–7.
- Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43: 518–24
- King A. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J Antimicrob Chemother 2001; 48(Suppl 1)77–80
- Gur D, Kocagoz S, Akova M. Comparison of E-test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother 1999; 43: 2337
- Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E-test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol 2005; 43: 140–3
- Rubinstein ER, Lang R, Shasha B, et al. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991; 35: 1925–7
- Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, et al. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis 2004; 36: 636–8
- Bodur H, Balaban N, Aksaray S, et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003; 35: 337–8
- Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004; 23: 405–7
- Yamazhan T, Aydemir S, Tunger A, Serter D, Gokengin D. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean Region in Turkey. Med Princ Pract 2005; 14: 413–6
- Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents 2005; 26: 101–5